Target Blood Pressure Goals in Patients with Chronic Kidney Disease: Where Do We Stand in this Era of Evidence based Medicine?

Q4 Medicine Open Hypertension Journal Pub Date : 2020-01-01 DOI:10.15713/ins.johtn.0212
S. Nagaraju, S. Shenoy
{"title":"Target Blood Pressure Goals in Patients with Chronic Kidney Disease: Where Do We Stand in this Era of Evidence based Medicine?","authors":"S. Nagaraju, S. Shenoy","doi":"10.15713/ins.johtn.0212","DOIUrl":null,"url":null,"abstract":"There is also a lot of emphasis in the last decade about BP measurement techniques. BP measurement by automated BP instruments or Abstract Chronic kidney disease (CKD) is highly prevalent globally and is strongly associated with cardiovascular disease (CVD). Hypertension affects the vast majority of patients with CKD and increases the risk of CVD, end-stage kidney disease, and mortality. Control of hypertension in CKD is very important in our clinical practice to slow the progression of CKD as well as to reduce CVD risk. Over the past 10 years, three major guidelines have dealt with blood pressure (BP) thresholds and targets for antihypertensive drug therapy in CKD patients: The 2012 Kidney Disease: Improving Global Outcomes Clinical Practice Guideline for the management of BP in CKD; the 2017 American College of Cardiology/American Heart Association 2017 Guideline for the Prevention, Detection, Evaluation, and Management of High BP in Adults; and the 2018 European Society of Cardiology and the European Society of Hypertension guidelines for the Management of arterial hypertension. These guidelines do not offer a consensus on optimal BP targets and have varying recommendations for BP goals in patients with CKD. It may leave practicing physicians and patients in a dilemma. Therefore, it is necessary to understand the existing evidence used to create these guidelines to deliver personalized management and achieve BP targets in CKD.","PeriodicalId":38918,"journal":{"name":"Open Hypertension Journal","volume":"146 6 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Hypertension Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15713/ins.johtn.0212","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

There is also a lot of emphasis in the last decade about BP measurement techniques. BP measurement by automated BP instruments or Abstract Chronic kidney disease (CKD) is highly prevalent globally and is strongly associated with cardiovascular disease (CVD). Hypertension affects the vast majority of patients with CKD and increases the risk of CVD, end-stage kidney disease, and mortality. Control of hypertension in CKD is very important in our clinical practice to slow the progression of CKD as well as to reduce CVD risk. Over the past 10 years, three major guidelines have dealt with blood pressure (BP) thresholds and targets for antihypertensive drug therapy in CKD patients: The 2012 Kidney Disease: Improving Global Outcomes Clinical Practice Guideline for the management of BP in CKD; the 2017 American College of Cardiology/American Heart Association 2017 Guideline for the Prevention, Detection, Evaluation, and Management of High BP in Adults; and the 2018 European Society of Cardiology and the European Society of Hypertension guidelines for the Management of arterial hypertension. These guidelines do not offer a consensus on optimal BP targets and have varying recommendations for BP goals in patients with CKD. It may leave practicing physicians and patients in a dilemma. Therefore, it is necessary to understand the existing evidence used to create these guidelines to deliver personalized management and achieve BP targets in CKD.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
慢性肾病患者的血压目标:在循证医学时代我们站在哪里?
在过去十年中,BP测量技术也得到了很多重视。摘要慢性肾脏疾病(CKD)在全球范围内非常普遍,并且与心血管疾病(CVD)密切相关。高血压影响绝大多数CKD患者,并增加心血管疾病、终末期肾病和死亡率的风险。在临床实践中,控制CKD患者的高血压对于减缓CKD的进展以及降低CVD的风险非常重要。在过去的10年里,有三个主要的指南处理了CKD患者的血压阈值和降压药物治疗的目标:2012肾脏疾病:改善CKD患者血压管理的全球结果临床实践指南;2017年美国心脏病学会/美国心脏协会2017年成人高血压预防、检测、评估和管理指南;以及2018年欧洲心脏病学会和欧洲高血压学会动脉高血压管理指南。这些指南并没有就CKD患者的最佳血压目标达成共识,并且对血压目标有不同的建议。这可能会让执业医生和患者陷入两难境地。因此,有必要了解用于创建这些指南的现有证据,以提供个性化管理并实现CKD的血压目标。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Open Hypertension Journal
Open Hypertension Journal Medicine-Cardiology and Cardiovascular Medicine
自引率
0.00%
发文量
0
期刊最新文献
Implementation of a Resistant Hypertension Control Program in a Low-income Primary Care Setting in a High-Income Country: Lessons Learned and Global Applicability Troponin and B-type Natriuretic Peptides Biomarkers in the Management of Hypertension Hypertension in end-stage kidney disease Confirming a Diagnosis of "Hypertension" Sodium-glucose Co-transporter 2 Inhibitors and Blood Pressure Reduction among Patients with Diabetes, Cardiovascular Disease, Chronic Kidney Disease
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1